EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Durable Response to Selpercatinib in Metastatic Colorectal Cancer Harboring a Novel TIMM23B::RET Fusion: A Case Report

Ziyan Tong, Mengyuan Yang, Shanshan Weng, Ying Yuan iD

Current Oncology · 07.05.2026 · 33 (5) · 271

DOI: 10.3390/curroncol33050271 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, online erschienen am 07.05.2026. Verfasst von Ziyan Tong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Pyridines, Pyrazoles, Proto-Oncogene Proteins c-ret. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RET fusions are rare but actionable oncogenic drivers in metastatic colorectal cancer (mCRC), occurring in a small molecular subset with limited clinical evidence for selective RET inhibition. We report a 77-year-old woman with mCRC harboring a rare TIMM23B::RET fusion who achieved durable benefit from selpercatinib after progression on capecitabine. Molecular profiling showed RAS/BRAF wild-type, microsatellite-stable disease with a TIMM23B::RET fusion. Selpercatinib induced a marked decline in tumor markers and a sustained partial response on serial imaging. Treatment was complicated by grade 3 hepatotoxicity, requiring temporary interruption and dose reduction to 80 mg twice daily. Despite this, disease control was maintained without further grade ≥ 3 toxicity. At the time of writing, the patient remains on treatment with progression-free survival exceeding 14 months. To our knowledge, this is among the first detailed reports of mCRC harboring a TIMM23B::RET fusion with documented clinical benefit from selpercatinib. This case highlights the value of comprehensive genomic profiling and individualized toxicity management in rare molecular subsets of mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsPyridinesPyrazolesProto-Oncogene Proteins c-retHumansFemaleAged

Stichwörter der Autor:innen

RET fusionTIMM23B::RETcase reportmetastatic colorectal cancerprecision oncologyselpercatinib

Substanzen

PyridinesselpercatinibPyrazolesProto-Oncogene Proteins c-retRET protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
  • Zhejiang Provincial Clinical Research Center for CANCER, Hangzhou 310009, China.
  • Cancer Center, Zhejiang University, Hangzhou 310058, China.
  • Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, Hangzhou 310009, China.

ORCID-Profile: Ying Yuan

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Tong, Z., Yang, M., Weng, S., & Yuan, Y. (2026). Durable Response to Selpercatinib in Metastatic Colorectal Cancer Harboring a Novel TIMM23B::RET Fusion: A Case Report. Current Oncology, 33(5), 271. https://doi.org/10.3390/curroncol33050271

Vancouver

Tong Z, Yang M, Weng S, Yuan Y. Durable Response to Selpercatinib in Metastatic Colorectal Cancer Harboring a Novel TIMM23B::RET Fusion: A Case Report. Current Oncology. 2026;33(5):271. doi:10.3390/curroncol33050271

BibTeX
@article{Tong2026,
  author = {Tong, Ziyan and Yang, Mengyuan and Weng, Shanshan and Yuan, Ying},
  title = {Durable Response to Selpercatinib in Metastatic Colorectal Cancer Harboring a Novel TIMM23B::RET Fusion: A Case Report},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {5},
  pages = {271},
  doi = {10.3390/curroncol33050271}
}
Kostenlos starten →